Please assess the completion status of the following clinical trial:

Trial Title: Levofloxacin-containing Therapies In Second Line Helicobacter Pylori Eradication

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Consecutive H. pylori-infected participants, at least 18 years of age, with endoscopically proven peptic ulcer diseases or gastritis who failed first-line eradication therapies with standard triple regimens (PPI twice daily, 500 mg of clarithromycin twice daily and 1 g of amoxicillin twice daily)~Exclusion Criteria:~* Ingestion of antibiotics, bismuth, or proton-pump inhibitors within the prior 4 weeks~* Use of non-steroidal anti-inflammatory drugs within the prior 4 weeks~* Participants with allergic history to the medications used~* Participants with previous gastric surgery~* The coexistence of serious concomitant illness (for example, decompensated liver cirrhosis, uremia)~* Pregnant women.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Sequential therapy (Type: EXPERIMENTAL): Esomeprazole (Nexium)(40 mg) 1 tablet twice daily, amoxicillin (Amolin)(500 mg) 2 tablets twice daily for 5 days followed by esomeprazole (Nexium) (40 mg) twice daily, levofloxacin(Cravit)(500 mg), 1 tablet once daily and metronidazole (Flagyl)(250 mg) 2 tablets three times daily for 5 days
- Triple therapy (Type: ACTIVE_COMPARATOR): Esomeprazole (Nexium)(40 mg) 1 tablet twice daily; amoxicillin (Amolin)(500 mg) 2 tablets twice daily and levofloxacin(Cravit)(500 mg), 1 tablet once daily for 10 days

Based on this trial design, predict the completion outcome and termination type (if applicable).